Memory Disorders Clinical Trials

Stanford Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Genentech (Lauriet Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: Moderate AD
Clinicaltrials.gov identifier:
NCT03828747
PI
: Sharon Sha, MD
Contact:
Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu
Inclusion criteria:

·       MMSE 16-21 (inclusive)
·       CDR (global) 1 or 2
·       Age 50-85
·       Stable AD meds for > 2 months

Active, not recruiting:

Sponsor: Biogen (Tango Study)
Intervention
: BIIB092 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier:
NCT03352557
PI
: Sharon Sha, MD
Contact:
Nischal Acharya, 650-460-9573, acharya5@stanford.edu

Sponsor: Genentech (Tauriel Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier:
NCT03289143
PI
: Sharon Sha, MD
Contact:
Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu

Upcoming:

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention
: Prazosin
Indication
: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier:
NCT03710642
PI
: Victor Henderson, MD and Sharon Sha, MD
Contacts:
Amanda Ng, (650)485-9560, amandang@stanford.edu

Completing, not recruiting:

Sponsor: Novartis (Generations II Study)
Intervention:
CNP520 (Active BACE-1 Inhibitor)
Target Population:
Cognitively Unimpaired APOE4 Homozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier:
NCT03131453
PI
: Sharon Sha, MD
Contacts:
Amanda Ng, (650)485-9560, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention:
CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population:
Cognitively Unimpaired APOE4 Homozygotes
Clinicaltrials.gov identifier:
NCT02565511
PI
: Sharon Sha, MD
Contacts:
Hanna Balcha, (650)223-9662, hannafb@stanford.edu

Sponsor: Eisai (MissionAD Study)
Intervention:
Elenbecestat (BACE 1 inhibitor)
Indication:
MCI/Mild AD
Clinicaltrials.gov identifier:
NCT02956486
PI
: Sharon Sha, MD
Contacts:
Hanna Balcha, (650)223-9662, hannafb@stanford.edu

Sponsor: Biogen (Emerge Study)
Intervention
: BIIB037 (Monoclonal antibody)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier:
NCT02484547
PI
: Sharon Sha, MD
Contact:
Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu

Sponsor: Genentech (Cread Study)
Intervention
: Crenezumab (Monoclonal antibody)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier:
NCT02670083
PI
: Sharon Sha, MD
Contact:
Jenn Gaudioso, 650-206-0963, jenn.gaudioso@stanford.edu

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072